Abstract

Hybrid Liposomes Inhibit the Growth and Angiogenesis in Human Breast Cancer Model.

Hideaki Ichihara, Shuichi Yamasaki, Motoki Hino, Ryuichi Ueoka and Yoko Matsumoto

Therapeutic effects of hybrid liposomes (HL-25) composed of L-α-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene(25)dodecyl ether (C12(EO)25) against breast tumor due to anti-angiogenic activity were examined in vitro and in vivo. Inhibitory effects of HL-25 on the formation of capillary tubes in the human umbilical vascular endothelial cells (HUVEC) were obtained in vitro. Remarkable reduction of tumor volume in mouse models of human breast cancer (HBC) was verified after the intravenous treatment with HL-25 without drugs in vivo. Anti-angiogenic activity in mouse models of HBC treated with HL-25 was observed on the basis of immunostaining method using CD34. Therapeutic effects along with anti-angiogenic activity of HL-25 without any drugs on the mouse models of HBC were revealed for the first time in vivo.